CB Scientific, Inc. announced that it has developed three core platform technologies; CannaRAPID™, CannaNASAL™, and CannaDERME™, focused on precise dosing and controlled release of cannabinoid compounds for patients. Furthermore, CB Scientific has developed Pain-Patch™ using CannaDERME transdermal delivery and smart device technologies for relieving various kinds of pains. CB Scientific is gearing up for conducting clinical studies using Pain-Patch for various indications. CB Scientific's will be Releasing 1st Gen Pain-Patch™, a Thermo-Responsive Cannabinoid Delivery Device for Targeted Delivery to Brain in second or third quarter 2017. Further, CB Scientific brings safe, quick and easy to determine results through fast detection kits. CB Scientific is also releasing a 4th generation Test4Kits, a fast cannabinoid detection kit, with a much more user-friendly and faster detection time. The cannabinoid compounds works through CB1 and CB2 receptors in body which is involved with a variety of physiological processes, including mood, pain, appetite, memory and cognitive function. CB1 is mainly aggregated in the brain, delivering some of these key functions. A major problem in the medical use of cannabinoids is the targeted and efficient delivery of cannabinoid compounds to neural tissues. Oral ingestion can cause the production of unwanted metabolites from cannabinoid compounds by liver and gut microbiota metabolism reducing the effective dose and creating unwanted side-effects. Further, sustained action of cannabinoid may not be possible by oral ingestion. There is a pressing need for precise dosing and targeted delivery of cannabinoids to brain by passing the first-pass liver metabolism. This is resolved through use of transdermal and other innovative methods. CB Scientific's novel pipeline of technologies and products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. CannaRAPID™ is proprietary sublingual delivery technologies using orally disintegrating tablet technology. CannaNASAL™ is a nasal delivery technology using liposomal nanoparticles and CannaDERME™ is transdermal technology using nano-emulsion for fast absorption of cannabinoid compounds. The technologies and formulations of these technologies are completed and medical device products based on these core-technologies are being developed. CB Scientific has developed Pain-Patch using a combination of CannaDERME transdermal delivery and smart device technology for relieving various kinds of pain symptoms. CB Scientific has formulated cannabidiol-based Pain-Patch for proof-of-concept studies. Highlights include: Cannabidiol is one of the key cannabinoid constituents in Hemp Plant. CBD is non-psychoactive and safe compound with a wide range of therapeutic applications, including the treatment of neural disorders and clinical studies have suggested a wide range of possible therapeutic effects of cannabidiol on several conditions. The Pain-Patch has transcutaneous cannabinoid penetration technology coupled with thermosensitive nano-emulsion for sustained release of compounds for longer time. The device delivers therapeutic doses to brain via brain stem for whole-body effect. The goal of these patches are to produce a pain-patch with a small footprint for easy concealment, a strong formula to counteract the decreased quality of life for individuals who suffer with systemic pain, a long shelf-life and the use of non-toxic and non-abrasive components to create the most comfortable and effective patch on the market using this technology. CB Scientific is gearing up for conducting clinical studies using Pain-Patch for various indications such as stress and anxiety relief, cognitive focus, various kinds of pain, migraines etc. CB Scientific is also expanding its portfolio of diagnostics and testing technologies by improving existing products and release of new products. CB Scientific has developed and marketed Test 4 kits Technology using a novel approach to rapidly detect THC, CBD and other cannabinoids from a variety of samples. Launched in 2015, first generation Test4 kits has been well received worldwide.